Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis

Targeting the α4β7-MAdCAM-1 axis with vedolizumab (VDZ) is a front-line therapeutic paradigm in ulcerative colitis (UC). However, mechanism(s) of action (MOA) of VDZ remain relatively undefined. Here, we examined three distinct cohorts of patients with UC (n=83, n=60, and n=21), to determine the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Canales-Herrerias, Pablo, Uzzan, Mathieu, Seki, Akihiro, Czepielewski, Rafael S., Verstockt, Bram, Livanos, Alexandra, Raso, Fiona, Dunn, Alexandra, Dai, Daniel, Wang, Andrew, Al-taie, Zainab, Martin, Jerome, Ko, Huaibin M., Tokuyama, Minami, Tankelevich, Michael, Meringer, Hadar, Cossarini, Francesca, Jha, Divya, Krek, Azra, Paulsen, John D., Nakadar, M. Zuber, Wong, Joshua, Erlich, Emma C., Onufer, Emily J., Helmink, Beth A., Sharma, Keshav, Rosenstein, Adam, Chung, Grace, Dawson, Travis, Juarez, Julius, Yajnik, Vijay, Cerutti, Andrea, Faith, Jeremiah, Suarez-Farinas, Mayte, Argmann, Carmen, Petralia, Francesca, Randolph, Gwendalyn J., Polydorides, Alexandros D., Reboldi, Andrea, Colombel, Jean Frederic, Mehandru, Saurabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882272/
https://www.ncbi.nlm.nih.gov/pubmed/36711839
http://dx.doi.org/10.1101/2023.01.19.524731

Ejemplares similares

Ejemplares similares